Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3 and removed Revision: v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-05T18:54:42.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    33 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.1 to v3.4.2; no core content or functionality changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-12T00:37:24.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    Revision: v3.4.1 was added, replacing Revision: v3.4.0, indicating a minor site version update. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:45:54.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    UI/metadata updates include adding a glossary display option, showing the label 'Last Update Submitted that Met QC Criteria', displaying 'No FEAR Act Data', and updating the revision to v3.4.0 (replacing v3.3.4) with minor capitalization adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-01-28T21:41:31.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no other study content or page functionality is affected.
    Difference
    0.1%
    Check dated 2026-01-14T04:11:29.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    Footer now displays Revision: v3.3.3; the HHS Vulnerability Disclosure line and the previous Revision: v3.3.2 have been removed.
    Difference
    0.1%
    Check dated 2025-12-23T22:37:10.000Z thumbnail image

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.